盐酸阿柔比星
| 中文名称 | 盐酸阿柔比星 |
|---|---|
| 中文同义词 | 盐酸阿柔比星;阿柔比星盐酸盐;阿克拉霉素盐酸盐 |
| 英文名称 | ACLARUBICIN HYDROCHLORIDE |
| 英文同义词 | aclacinomycinahydrochloride;aclacinon;n-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyrano;syl)oxy)-2,5,7-trihydroxy-,methylester,hydrochloride,(1r-(1-alpha,2-beta,4;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-l-lyxo;ACLARUBICIN HYDROCHLORIDE;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, meth;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, methyl ester, hydrochloride, [1R-(1α,2β,4β)]- |
| CAS号 | 75443-99-1 |
| 分子式 | C42H54ClNO15 |
| 分子量 | 848.33 |
| EINECS号 | 278-209-3 |
| 相关类别 | API |
| Mol文件 | 75443-99-1.mol |
| 结构式 |  |
盐酸阿柔比星 性质
| 熔点 | 151-153℃ |
|---|---|
| 沸点 | 898℃ |
| 闪点 | >110°(230°F) |
| 储存条件 | 2-8°C |
| 溶解度 | 溶于DMSO或DMF，浓度为25mg/ml |
20S proteasome.
Topoisomerase I and II.
Aclacinomycin A could efficiently enter living cells and emit fluorescence
in situ
. Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM Acla for 15 min) results in approximately 20% dead (or nearly dead) cells.
Aclacinomycin A (Aclarubicin) effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34 .
Aclacinomycin A is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD
50
(76.5 mg/kg) is about twice the iv LD
50
(35.6 mg/kg) in mice
[4
.
Aclacinomycin A (0.75-6 mg/kg, ip daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model
[4
.
| Animal Model: | DBA/2, CDF 1 (BALB/c×DBA/2) mice with Leukemia P-388 [4 . |
| Dosage: | 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. |
| Administration: | Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. |
| Result: | Inhibited tumor growth. |
安全信息
| 危险品标志 | T |
|---|---|
| 危险类别码 | 23/24/25 |
| 安全说明 | 36/37/39-45 |
| 危险品运输编号 | 3249 |
| RTECS号 | QI9283500 |
| 危险等级 | 6.1(a) |
| 包装类别 | II |
盐酸阿柔比星 化学药品说明书
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2023/01/06 | HY-N2306A | 盐酸阿柔比星 Aclacinomycin A hydrochloride | 75443-99-1 | 5mg | 2800元 |
| 2023/01/06 | HY-N2306A | 盐酸阿柔比星 Aclacinomycin A hydrochloride | 75443-99-1 | 10 mM * 1 mLin DMSO | 4479元 |